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ABSTRACT
Objectives: Endometriosis is considered as a chronic pelvic inflammatory disease and prostaglandin E2(PGE2) (a kind of 
the inflammatory cytokines) was increased in the endometriosis patient’s peritoneal fluid . Ca2+ signal and Ca2+ channels 
play an important role in cell apoptosis. This study was to explore the L-type calcium channel (Cav1.3) expression and its 
biological function in endometriosis. Furthermore the molecular mechanism between Cav1.3 and PGE2 was also clarified.
Material and methods: The real-time PCR and immunohistochemical were used to detect the expression of Cav1.3.  
Apoptosis was detected by Flow cytometry assay and Western blot assay.
Results: Cav1.3 was high expression in endometriosis tissue and primary endometrial stromal cells (hEM15A). Treatment 
with PGE2 rapidly inhibited apoptosis and increased Cav1.3 expression in hEM15A . The silencing of Cav1.3 promoted ap-
optosis, which was unchanged after PGE2 treatment. Moreover, the inhibition of Cav1.3 by shRNA transfection activated 
cleaved PARP and cleaved caspase-3. 
Conclusions: These available evidences suggest that Cav1.3 is required for PGE2 induction apoptosis and relates to the 
pathophysiology of endometriosis. Interference with Cav1.3 may offer a neo-therapeutic window in endometriosis treatment.
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INTRODUCTION
Endometriosis (EM), which is characterized the pres-
ence and growth of endometrial glands and stroma outside 
the uterine cavity, affects about 10–15% of reproductive 
women and up to 24–50% in infertile women [1, 2]. Clini-
cal manifestations of endometriosis include pelvic pain, 
dysmenorrhea, dyspareunia and infertility. For the majority 
of these patients, surgery and/or hormonal therapy remain 
the primary therapy of choice. However, hormonal therapy 
usually is associated with serious adverse effects and endo-
metriosis lesions relapse in 30–50% women within 3–5 years 
after surgery [3]. Therefore, to explore the pathogenesis 
mechanism of endometriosis and find a novel therapy is 
imperative.
Generally, endometriosis is perceived as a chronic pelvic 
inflammatory process with systemic subclinical manifes-
tations. Peritoneal fluid from women with endometriosis 
shows activated defective macrophages and natural killer 
cells which alter the recognition and clearance of endome-
trial cells. Macrophages secrete different products such as 
growth factors, enzymes, prostaglandins, and cytokines 
that stimulate and promote the progression of endometrio-
sis [4] . Especially for prostaglandin E2 (PGE2), which high 
expresses in abdominal fluid and blood in endometriosis 
patient, induces a classical inflammatory responses [5]. 
PGE2 is a mediator of many biological functions as well as 
active inflammation, which promotes local vasodilatation 
with recruitment and activation of inflammatory cells [6]. 
PGE2 triggers a range of cellular responses through bind-
ing with receptors (EP1, EP2, EP3 and EP4) [7, 8], which 
causes activation of PKC accompanied by cytosolic Ca2+ 
mobilization [9]. 
Ca2+ channels tightly modulated Ca2+ homeostasis 
which regulates second messenger pathway. Ca2+ channels 
introduce Ca2+ into the cytoplasm and participate in regu-
lating cell functions, which include cell pattern formation, 
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differentiation, proliferation, migration, death and so on [10]. 
The L-type Ca2+ channel subunit α 1D, named Cav1.3, is 
highly expressed in prostate cancer, endometrial cancer and 
breast cancer, which participate tumorigenesis [11–13]. Also, 
Cav1.3 regulates calcium-dependent mitochondrial oxidant 
stress in Parkinson’s disease [14]. Cav1.3 plays a well-known 
role in the occurrence and formation of many diseases, but 
its role in endometriosis is not clear.
In this study, we analyzed Cav1.3 expression in endome-
triosis patient using real-time PCR and immunohistochem-
istry assays; the relationship between Cav1.3 and PEG2 was 
investigated and the signaling pathway in primary endo-
metrial stromal cell (hEM15A) was detected. Further, the 
effect of apoptosis by short hairpin (sh)RNA in hEM15A was 
assessed. The study might explore new insights into the 
treatment of endometriosis in clinical practice.
MATERIAL AND METHODS 
Patients 
In total, 30 ovarian endometriosis and 30 normal endo-
metrial tissues were collected from patients undergoing first 
curative treatment resection in the Department of Obstetrics 
and Gynecology of the 1st Hospital of Lanzhou University 
(Lanzhou, China) between January 2017 and December 
2017. None enrolled patients received hormonal therapy 
before surgery therapy. Moreover, 30 ovarian endometrio-
sis samples diagnosed as endometriosis according to the 
American Society for Reproductive Medicine classification of 
endometriosis criteria [15]. The study was approved by the 
Ethics Committee of the 1st Hospital of Lanzhou University 
(No.LDYYLL2019-148) and each patient signed informed 
consent. 
Immunohistochemistry 
The paraffin sections of tissues were dewaxed as routine. 
0.3% hydrogen peroxide methanol closed endogenous per-
oxidase for 30 minutes. After exposing 10% unimmunized 
goat serum to PBS for 10 minutes, the sections were treated 
with rabbit primary anti-cav1.3 antibody at 4°C overnight 
(1:200, Abcam, USA). Sections were incubated with bioti-
nylated anti-rabbit immunoglobulin serum for 30 minutes, 
and then incubated with peroxidase-labeled avidin at room 
temperature for 20 minutes. Diaminobenzidine hydrochlo-
ride was used as chromogenic reagent. Finally, the sections 
were counter stained with hematoxylin. With percentage 
score (0~9) multiplied by the strength calculation expres-
sion of Cav1.3, final score < 4 patients for lower expression 
group, vice for low expression group.
Cell culture, treatment and reagents
hEM15A was purchased from China center for type cul-
ture collection and cultured as instruction [16]. Cell transfec-
tion involved use of lipofectamine 2000 (Invitrogen, USA) 
with Cav1.3 shRNA according to the manufacturer’s protocol. 
The primer sequence for Cav1.3 shRNA was designed by 
Shanghai GenePharma Co. ,Ltd. The efficiency of knocking 
down the target proteins were detected by western blot assay.
Real-time PCR
Conventional Trizol method (TRI Reagent) is used to ex-
tract total RNA. The first strand of cDNA was synthesized us-
ing the Prime Script reverse transcriptase kit (TaKaRa, dalian, 
China) according to the manufacturer’s instructions. Specific 
primers are as follows:β-actin: forward 5’-CACCATCCTG-
GCCTCGCTGT-3’, and reverse 5’-GCTACCTTCACCGTTCC-3’; 
Cav1.3: Forward: 5’- TCCAGGCAAAAACACTTCAAGG-3’ and 
Reverse:5’- GGAGGCTCT CACTGGCAAAT-3’. 
Flow cytometry assay
Annexin-v /FITC kit (BD Biosciences, San Jose, CA, USA) 
was used to detect apoptosis as per the manufacturer’s 
instructions, and flow cytometry was used for analysis fol-
lowing the series of treatments described previously [17].
Western blot assay
hEM15A was harvested and lysed. Total protein was 
extracted and quantified according to the manufacturer’s 
instructions. Western blot assay was performed as described 
previously [18] anti — Cav1.3 polyclonal antibody (1:1000, 
Abcam, USA), cleaved caspase 3/caspase 3 (1:1000, Abcam, 
USA), cleaved PARP/PARP (1:1000, Abcam, USA) were used. 
Use ECL substrate to detect its expression. Intensity bands are 
detected by the Bio-rad imaging system (Hercules, CA, USA).
Statistical Analysis
Data were expressed as mean ± standard deviation and 
analyzed by GraphPad Prism 5 software. Student’s t-test was 
used for the comparison of the two groups, one-way analysis 
of variance was used for the comparison of the multiple 
groups, and Tukey’s test was used for the comparison of 
the two groups. When the square difference between two 
groups is not even, non-parametric test is used. p < 0.05 was 
considered statistically significant.
RESULT
Cav1.3 high expressed in endometriosis tissues 
Real-time PCR analysis was used to identify the dif-
ferent expression of Cav1.3 in endometriosis (EM) and 
normal endometrial (EN) tissues. Cav1.3 was significantly 
upregulated in EM tissues (n = 30) compared with in EN 
tissues (n = 30) (p < 0.01) (Fig. 1A). Moreover, the protein 
expression of Cav1.3 was detected by immunohistochem-
istry in the ovarian endometriosis. A total of 68.0% of 
ovarian endometriosis were positive for Cav1.3 staining in 
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the nucleus and cytoplasm (Fig. 1B). Also, the Cav1.3 was 
highly expressed in hEM15A. Therefore, Cav1.3 was 
knocked down by transfecting hEM15A with shRNA. The 
efficiency about knockdown Cav1.3 protein was detected 
by Western blot after 48 h The result showed that the 
protein of Cav1.3’s expression was significantly reduced 
in shRNA transfection hEM15A compared with negative 
control cells (p < 0.01) (Fig. 1C).
Cav1.3 shRNA promoted apoptosis in hEM15A 
Because Cav1.3 was upregulated in endometriosis and 
hEM15A , the biological role of Cav1.3 in hEM15A was ex-
amined. The Cav1.3 shRNA cells and Cav1.3-negative control 
cells were analyzed by flow cytometry to determine whether 
Cav1.3 inhibited cell death through decreasing apoptosis. The 
results showed that the apoptotic cells increased strikingly 
in Cav1.3 shRNA-transfected cells, as compared with controls 
(p < 0.01). Furthermore, after 50 μM PGE2 treated 24 h, PGE2 in-
hibited the apoptosis in Cav1.3-negative control cells. Howev-
er, the apoptosis was unchanged in Cav1.3 shRNA-transfected 
cells after PGE2 stimulation 24 h (p > 0.05) (Fig 2).
PGE2 suppressed apoptosis by Cav1.3/PARP/
caspase3 in hEM15A 
To further investigate the mechanism of apoptosis in 
hEM15A , the expression of Cav1.3, cleaved caspase3 and 
poly-ADP-ribose polymerase (PARP) were detected by 
western blot in hEM15A. After 50μM PGE2 treated 24 h, 
the result revealed that Cav1.3 increased in Cav1.3-neg-
ative control cells (p < 0.01), but cleaved PARP and cas-
pase 3 were decreased in Cav1.3-negative control cells 
(p < 0.01). Meanwhile, after 50 μM PGE2 treated 24 h in 
Cav1.3 shRNA-transfected cells, Cav1.3,cleaved PARP and 
caspase3 were unchanged (p > 0.05). The result revealed 
that PGE2 can upregulated the expression of Cav1.3, 
which inhibited hEM15A ’ apoptosis by down-regulated 
cleaved PARP and caspase3 (Fig. 3).
DISCUSSION
Our results show that Cav1.3 was upregulated in endo-
metriosis and hEM15A. In addition, upregulated Cav1.3 in-
hibited apoptosis in hEM15A. Moreover, PGE2 suppressed 
apoptosis by upregulated Cav1.3’s expression in hEM15A. 
The results suggested that Cav1.3 expression plays a crucial 
apoptosis role in endometriosis progression. The mecha-
nistic study showed that PGE2 suppressed apoptosis by 
upregulated Cav1.3 expression, which finally decreased 
cleaved PARP and caspase3 in hEM15A. This study proposes 
a novel mechanism that PARP/caspase3 pathway are the 
responsible factors for the high expression of Cav1.3 after 
PGE2 stimulation.
To our knowledge, the research about apoptosis role of 
Cav1.3 is little in endometriosis. Recent study show that in-
creased expression of Cav1.3 in prostate cancer induces 
Figure 1. Expression of Cav1.3 in endometriosis tissues and hEM15A; A. Realtime PCR analysis of Cav1.3 expression levels in endometriosis 
(EM) and normal endometrial (EN) tissues (**p < 0.01); B. IHC staining of Cav1.3 expression in ovarian endometriosis (① — low expression; ② 
— moderate expression; ③ — high expression) × 400; C. The expression of the channel protein Cav1.3 after shRNA transfection was significantly 
reduced compared with that of NC cells (**p < 0.01)
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androgen mediated cell growth [11]. In endometrial cancer 
cells, estrogen upregulates Cav1.3’s expression by GPR30, 
which activates the erk1/2/CREB pathway, initiates calcium 
influx through Cav1.3, and promotes cell proliferation and 
migration [12]. In breast cancer, Cav1.3 is high expressed 
and activated Ca2+ influx promoting cell proliferation [13]. 
Our study showed that Cav1.3 was significantly upregulated 
in endometriosis tissues and hEM15A. Reducing Cav1.3 sig-
nificantly promoted apoptosis in hEM15A. PGE2 upregu-
lated the expression of Cav1.3 and inhibited apoptosis by 
down-regulated the protein of cleaved caspase3 and PARP. 
These data support the suggestion that Cav1.3 may act 
an important role in endometriosis progression through 
regulate cell apoptosis. 
Apoptosis refers to the cell regulated by genes in order 
to maintain the stability of the internal environment, which 
Figure 2. Cav1.3 shRNA promoted apoptosis in hEM15A; A. Cells transfected with shRNA Cav1.3 was stained with Annexin-V-FITC. Apoptosis 
analysis was performed by flow cytometry; B. The bar graph showed a significant increase in the apoptotic index (*p < 0.05)
Figure 3. PGE2 suppressed apoptosis through Cav1.3/PARP/caspase3 in hEM15A. Cav1.3 increased in Cav1.3-negative control cells after 50μM 
PGE2 treated 24 h (**p < 0.01), meanwhile, cleaved PARP and caspase3 were decreased after 50μM PGE2 treated 24h in Cav1.3-negative control 
cells (**p < 0.01). After 50μM PGE2 treated 24h in Cav1.3 shRNA-transfected cells, Cav1.3,cleaved PARP and caspase3 were unchanged (p > 0.05). 
Cleaved PARP and caspase3 were activated after knocking down Cav1.3 in hEM15A (*p < 0.05)
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is not a phenomenon of self-injury under pathological con-
ditions, but a death process actively fought for to better 
adapt to the living environment [19]. The cytomorphological 
features of apoptosis include: cells are rounded, chromatin 
condensed and fragmented, and the cytoplasm is shrunken. 
After that, the whole cell forms some spherical processes 
by means of germination and foaming, and breaks off at its 
base to form apoptotic corpuscles containing cytoplasm, 
organelles and nuclear fragments of different sizes, which 
are then devoured by surrounding cells. Also there are other 
biological features which include controlled by genes, not 
caused by inflammation, plasma membrane does not break 
and so on [20]. Abnormal apoptosis relates with the inci-
dence of tumors, autoimmune diseases, neurodegenerative 
diseases.
PARP is a molecular cell receptor that can effectively 
monitor DNA damage in cells, repair damage and in-
duce apoptosis. When a large amount of DNA damage is 
not effectively repaired, the cell protection function of 
PARP changes. The damaged cells bypass the DNA dam-
age regulation electricity and clear from the organism 
through a predetermined self-destruction process, which 
is apoptosis. Once apoptosis is activated, PARP will partici-
pate in the process of apoptosis in the form of substrate. 
The proteolysis of PARP by caspase3 is an early event or 
prerequisite of apoptosis. Caspase3 is a key protease 
in apoptosis, which is at the core of apoptosis cascade 
reaction pathway and is considered as a death protease. 
A variety of apoptosis-stimulating factors initiate dif-
ferent protease cutting of prokaryogen caspase3 and 
activate caspase3, and the activated caspase3 further 
cuts different substrates, leading to the amplification of 
protease cascade reaction cutting and finally leading to 
apoptosis of cells. Caspase3 is a necessary pathway for 
the cascade of apoptotic proteins [21]. In this study, our 
results demonstrated that the cleaved caspase3 and PARP 
were activated through up-regulating of Cav1.3 after 
PGE2 stimulation. However, the mechanism underlying 
how Cav1.3 activated cleaved caspase3 and PARP need 
further investigation.
In conclusion, the available evidence suggests that 
Cav1.3 is required for PGE2 induction anti-apoptosis, 
contributes broadly to the pathophysiology of endome-
triosis. Interference with the calcium channel Cav1.3 may 
offer a new therapeutic window for endometriosis treat-
ment.
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